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Capsule summary:  
 What is already known about this topic 
- Ultraviolet (UV) B radiation increases serum 25-hydroxyvitamin-D3 
What this article adds to our knowledge 
- Phototherapy with UVA/UVBnb increased 25(OH)D serum level significantly 
- UVA1 therapy alone induced a reduction in serum 25(OH)D concentrations.  
How this information impacts clinical practice and/or changes patient care 
- Particular wave-lengths such as UVA1 and presumably also sunbeds which emit 
mainly UVA may not be helpful for vitamin D synthesis or even be detrimental, 
thus calling for attention to oral vitamin D supplementation in individuals 
concerned. 
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Abstract 
Background: Ultraviolet (UV) B radiation increases serum 25-hydroxyvitamin-D3 
[25(OH)D], but the influence of UVA1 and UVA/UVBnb phototherapy on serum vitamin D 
is unknown.  
Objective: To investigate the influence of narrowband UVB (UVBnb), UVA1 and 
UVA/UVBnb phototherapy on serum levels of 25(OH)D and related parameters in 
patients with an inflammatory skin condition.  
Methods: 25(OH)D, as well as calcium, parathormone, phosphate and albumin were 
measured before therapy, two weeks after start as well as after completion of the 
phototherapy at week 12. Diagnoses were divided in four groups: atopic dermatitis, 
psoriasis, morphea and others. 
Results: We surveyed 116 dermatological patients undergoing phototherapy with UVA1 
(n=38), UVA/UVBnb (n=29) or UVBnb (n=49) two to three times a week for 53-90 days. 
UVBnb phototherapy increased serum 25(OH)D from 22.1 to 39.5ng/ml after the therapy 
(p<0.001). The lower the baseline 25(OH)D level was, the steeper the increase in 
25(OH)D was upon application of UVBnb phototherapy. UVA/UVBnb therapy also 
increased serum 25(OH)D, from 23.9 to 50.3ng/ml (p=0.003). Conversely, in the UVA1 
therapy group, 25(OH)D serum levels decreased significantly from 21.9 to 19.0ng/ml 
(p<0.001).  
Limitations: The study design: open randomized trial without randomization. An 
influence of a precise skin disease cannot be excluded because of the heterogeneous 
diagnoses. Bias may have arisen from patient preference for treatment at our center, 
from referral, from unrecognized differences in underlying skin disease and other factors.  
Conclusion: Phototherapy with UVBnb and UVA/UVBnb increased 25(OH)D serum 
level significantly. UVA1 therapy alone induced a reduction in serum 25(OH)D 
concentrations.  
 3 
INTRODUCTION  
Phototherapy with ultraviolet light is a safe and effective treatment for a variety of 
inflammatory skin diseases. After replacing the broadband UVB (280-320 nm), 
narrowband UVB (311 nm) has become the first-line phototherapy due to its high 
efficacy and safety. UVB phototherapy has been shown to increase serum 25(OH) D 
concentrations in several studies.1, 2  
 
In the last decade, ultraviolet A1 (UVA1, 340-400nm) phototherapy has emerged as a 
therapeutic modality in sclerosing and inflammatory skin conditions, and vitamin D has 
been identified as important mediator in inflammatory skin disease.3 No data is available 
on vitamin D level variations under UVA1 phototherapy. A randomized controlled trial 
showed a significant increase in 25(OH)D serum levels after use of sunbeds emitting 
0.5% and 1.4% UVB.4 A significant increase in 25(OH)D had also been described after 
use of UVA sunbeds emitting only 0.36% of UVB.5 
 
Although the action spectrum for the conversion of 7-dehydrocholesterol to vitamin D3 is 
thought to be within the UVB range (280-320 nm), these results suggest that the higher 
wavelengths of UVA (320-400 nm) may as well have an effect. Nevertheless, the 
possibility that the small amounts of UVB emitted by these lamps might explain the 
increase either alone or in combination with UVA has not been ruled out. We 
investigated the serum levels of 25(OH)D under UVBnb, UVA/UVBnb and UVA1 
phototherapy.6  
 
MATERIALS AND METHODS 
Design 
An open observational study was conducted at Zurich University Hospital, Zurich, 
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Switzerland, from April 2009 to February 2011. The objective was to investigate the 
influence of UVBnb (311nm), UVA/UVBnb (320-400nm/311nm) and UVA1 (340-400nm) 
therapy on the serum vitamin D level measured as 25-hydroxyvitamin D3 [25(OH)D]. 
The Medical Ethics Committee of Zurich approved the study (H-B-2007-100), which was 
conducted according to the Declaration of Helsinki principles. All participants gave oral 
and written informed consent.  
 
Patients  
Weight and height were recorded and the body mass index (BMI) was calculated. The 
inclusion criteria were: Adult patients with a skin disease and the dermatological 
indication for a phototherapy with UVBnb, UVA/UVBnb or UVA1 as well as oral and 
written informed consent. The phototherapy was chosen according to the skin disease 
(for example psoriasis is treated with UVBnb, morphoea with UVA1; cf. Table 3). 
Participants were excluded from for the study if they did not complete the phototherapy, 
had a break of 2 weeks or more in the phototherapy course, or withdrew their consent to 
participate (Figure 1). Diagnosis groups were defined as follows: morphea/scleroderma 
(group 1), atopic dermatitis (group 2), psoriasis (group 3) and other (group 4) (Table 3).  
 
Definition of vitamin D sufficiency 
According to the World Health Organization, in this study, vitamin D insufficiency is 
defined as 25(OH)D level <20 ng/ml (< 50 nmol/L) and vitamin D deficiency as 25(OH)D 
level <10 ng/ml (< 25 nmol/L).7 
 
Statistical considerations and methods 
A minimum of 90 patients needed to enter this study. The study was aimed to detect a 
relationship between the cumulative UV dose and dependent variables at a two-sided 
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5.000 percent significance level. The true change in the dependent variables is 0.531 
standard deviations per one standard deviation change in the cumulative UV dose. 
Descriptive statistics of all the variables in the dataset were analyzed: mean, standard 
deviation, median, and IQR for continuous variables and frequencies and relative 
frequencies for discrete variables.  
 
Associations between two discrete variables were investigated by Chi-Square test. For 
paired discrete variables the McNemar test was applied. Mann-Whitney test was used in 
order to disclose differences in means of a continuous variable between two groups. In 
order to investigate differences in a continuous variable with respect to discrete factor 
with more than two levels, the one-way ANOVA together with the Scheffé post-hoc test 
was computed. Possible linear associations between two continuous variables were 
analyzed by means of the non-parametric Spearman correlation. The influence of time 
on continuous variables was investigated by the paired t-test. In order to gain the global 
view of the associations within the data set the multiple linear regression analysis was 
applied. Data were coded in Excel and analyzed in SPSS version 19. Results of the 
statistical analysis with p-value smaller than 5 percent were considered to be statistically 
significant. 
 
Agent doses and administration 
Patients enrolled in the study underwent phototherapy with UVBnb, UVA/UVBnb or 
UVA1 in the physical therapy unit of the Department of Dermatology according to the 
standard light therapy algorithm. Generally, UVBnb treatment is initiated at 0.1 J/cm2 per 
session and is increased in increments of 20% from session to session, provided there 
are no side effects, such as UV-induced erythema, limiting further dose escalation. The 
typical maximum dose for UVBnb is 2.0 J/cm2, but is individually adjusted based on the 
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clinician’s discretion. Typically, three sessions are performed weekly for a maximum of 
12 weeks. Generally, UVA1 treatment is initiated after phototesting on a small area and 
conducted at 50 J/cm2 per session. The typical maximum dose for UVA1 is 50 J/cm2 
(medium-dose UVA1). Typically, three sessions are performed weekly for a total of 30 
sessions resulting in a cumulative dose of 1500 J/cm2. The UVA/UVBnb treatment 
protocol consists of parallel application of UVA at a starting dose of 0.5 J/cm2 with 
increments of 20% increasing to a maximum dose of 5 J/cm2 during the standard 
UVBnb phototherapy. 
Phototherapy was performed with an UVBnb lamp (Waldmann, UV 1000, output 310 - 
315 nm, peak 311 nm), an UVA/UVBnb lamp (Waldmann, UV 7002, UVA: output 320 - 
410 nm, peak 351 nm; UVB output 310 - 315 nm, peak 311 nm) and a UVA1 lamp 
(Sellamed 24’000, output 340–420 nm, peak 380 nm). The UV sources irradiated all 
body surface areas with equal intensity. No radiation in the infrared or UVB region was 
detectable in the UVA1 lamp. 
 
Clinical evaluation 
Clinical examination of the skin was performed on day 0, day 14 and at completion of 
therapy at about 12 weeks.  
 
Laboratory measurements 
Serum 25(OH)D, as well as plasma levels of calcium, parathormone, phosphate, 
albumin and CRP levels were measured at day 0, day 14 and at completion of therapy at 
about 12 weeks. Calcium level was corrected with albumin level. 
 
Study completion 
 7 
A patient was considered to have completed the study after visit 3 and the last blood 
sampling. 
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RESULTS 
Of 126 screened patients, eight refused to participate or were not included because they 
could not complete phototherapy in our phototherapy unit. Two were excluded being 
minors below 18 years of age. We surveyed 116 dermatological patients undergoing 
phototherapy with UVA1 (n=38), UVA/UVBnb (n=30) or UVBnb (n=48) two to three times 
a week for 53-90 days. Of 116 participants (54 females and 62 males aged 18-83 years, 
median age 49.7 years old; women 47.2, men 48.4) entering the study, a total of 84 
participants completed the study (Figure 1). Reasons for dropouts were loss to follow-up 
in 31 patients and exclusion in one patient because phototherapy was changed to 
PUVA-therapy. 
  
Population parameters before therapy 
The age was similar across all therapy groups (p= 0.905). The baseline 25(OH)D level 
was comparable in all 3 groups before therapy as well as between the different 
diagnosis groups (p= 0.851). 
 
Influence of phototherapy on 25(OH)D concentrations 
Serum levels of 25(OH)D increased under UVBnb therapy, from 22.1 (+/- 10.3) to 39.5 
(+/- 12.2) ng/ml (increase 18.6 +/- 4.6 ng/ml; p<0.001). This effect was already 
detectable after 2 weeks of phototherapy (p<0.001) (Figure 2a, Figure 2b, Table 2). The 
increase in 25(OH)D level after UVBnb exposure correlated inversely with baseline 
25(OH)D level (P<0.001), where the patients with the lowest basal 25(OH)D level 
showed the most pronounced increase. 
UVA/UVBnb therapy increased 25(OH)D from 23.9 (+/- 20.2) to 50.3 (+/- 22.9) ng/ml by 
week 12 (increase 29.7 +/- 3.7 ng/ml; p=0.003). However, this increase was not 
significant at 2 weeks (p= 0.157) (Figure 2a, Figure 2b, Table 2). No difference was 
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detected in the increase of 25(OH)D between UVBnb and UVA/UVBnb phototherapies 
(p=0.652). In both UVBnb and UVA/UVBnb phototherapies, a relationship between the 
cumulative UVBnb dose and the increase in vitamin D could not be observed. 
 
On the other hand, under UVA1 therapy, a decrease in the 25(OH)D serum level from 
21.9 (+/- 9.7) to 19.0 (+/- 8.3) ng/ml was measured between week 0 and week 12 
(decrease -1.1 +/- 3.3 ng/ml; p<0.001; figure 2b). This effect was not detectable yet at 2 
weeks (p= 0.217) (Figure 2a). A trend for a relationship between the cumulative UVA1 
dose and the vitamin D decrease was observed (p= 0.0983). 
 
Before therapy with UVBnb there were eight insufficient (<20 ng/ml) and five deficient 
(<10 ng/ml) patients, and only two showed an insufficiency after therapy (no deficiency). 
In the UVA/UVBnb group, there were five insufficient and four deficient patients before 
therapy and only one insufficient patient after therapy (no deficient ones), respectively. In 
the UVA1 group, 14 patients had an insufficient 25(OH)D serum level and one was 
deficient in 25(OH)D. After UVA1 therapy, we detected 15 insufficient and five deficient 
patients. 
 
Influence of gender on serum vitamin D level 
No gender difference was observed in any single treatment group.  
 
Influence of season on serum vitamin D level 
Blood samples taken in winter and spring were grouped together as “winter”(w), in 
summer and fall grouped together as “summer”(s). Patients were then classified into 4 
different groups, depending on when they had the 1st and the 2nd blood sampling (w-w, 
w-s, s-w, s-s). Before therapy, the vitamin D serum level was significantly lower in the 
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winter group (p = 0.012, table 1). But the effect of phototherapy was independent of the 
season: We did not observe a relationship between these 4 groups and the vitamin D 
serum level (p= 0.125 for UVA1, p= 0.467 for UVA/UVBnb, p= 0.147 for UVBnb, p= 
0.150 for all therapy groups together) at the end of therapy.  
 
Influence of phototherapy on the other parameters 
The plasma levels of albumin-corrected calcium, phosphate, parathormone and CRP 
were not influenced by any of the phototherapies. Changes in systolic and diastolic 
blood pressure were not correlated to 25(OH)D serum level change. BMI, age and 
diagnosis were neither correlated to serum 25(OH)D change nor to phototherapy used. 
We did not observe any correlation between age and vitamin D synthesis (p values in 
Table 1). 
 
Quality of life and phototherapy 
DLQI improved in the total patients’ collective (p<0.001), as well as in each phototherapy 
group considered separately, however, we could not detect a difference between the 
phototherapy groups. DLQI did not correlate with the change in the vitamin D serum 
level.  
  
DISCUSSION 
Our study confirms the results of previous studies showing that UVBnb phototherapy 
increases serum vitamin D levels. In a case series of women with psoriasis, UVB 
broadband treatment for 8-12 weeks increased serum levels of 25(OH)D 1.62-fold from 
base level.8 Almost all studies were performed with UVB broadband and only seven 
recent studies investigated the plasmatic increase of vitamin D under UVBnb.9-15 
Czarnecki et al. showed that one oral dose of 50’000 IU of cholecalciferol raised the 
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serum level by 3.5 mmol/l on average, which was similar to the effect of one dose of 
UVBnb to the entire body surface.13 Only one study observed a vitamin D increase in the 
plasma under psoralen-UVA therapy, however the authors could not exclude a role for 
the small amount of UVB emitted by the lamp.16 
 
Our observation that individuals with low initial concentrations of 25(OH)D have a higher 
response to UVBnb irradiation confirmed previous reports.4, 11, 17 We did not find any 
correlation between the cumulative dose of UVBnb and the increase of serum 25(OH)D 
at 12 weeks, in accordance with Osmancevic et al.14 but in contradiction to a recent 
study.18 The explanation might be that 25(OH)D reaches a plateau after 3 weeks 
already, and that exposure to additional UVBnb may not result in a continued 
proportional increase in serum vitamin D.19  
 
Importantly, UVBnb as well as UVA/UVBnb therapies increased vitamin D serum levels 
in most insufficient and deficient individuals to the normal range, whereas therapy with 
UVA1 slightly reduced the vitamin D serum level, and resulted in an increased number of 
insufficient and deficient patients. This observed decrease of serum vitamin D after 
UVA1 phototherapy has not been documented to date. A possible explanation is that 
vitamin D absorbs UVA1 besides UVBnb and becomes susceptible to degradation.20 
Although the decrease is statistically significant, we cannot conclude that the effect of 
UVA1 on 25(OH)D is biologically relevant. However, we demonstrate that there is no 
25(OH)D increase with this wavelength. 
 
We found that the season when the therapy took place had no significant influence on 
the vitamin D level increase during UV therapy, both when considering all therapies 
together and each treatment modality separately. This is comparable to the results from 
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Lesiak et al., showing that vitamin D serum level changes with UVBnb were related to 
the season of the irradiation after 10 phototherapy sessions, but not after 20; our data 
were recorded after 12 weeks of phototherapy, representing about 36 sessions, a 
duration of such length that we expected no differences.15 
 
Our finding that the plasma level of calcium, phosphate, and CRP were not influenced by 
any of the phototherapies is in accordance to previous studies.8, 12, 14 The PTH level was 
inversely correlated to serum 25(OH)D levels, but the PTH level changes were not 
significant in any of the phototherapy groups. This cannot be explained by an insufficient 
increase in vitamin D serum level, as most patients that were insufficient or deficient 
before therapy had vitamin D in the normal range after UVBnb or UVA/UVBnb therapy. 
Our results are in accordance with the studies of Osmancevic et al., reporting a 
suppression of PTH along with an increase in vitamin D synthesis under UVBbb and 
UVBnb therapies but significant only under UVBbb therapy.8, 12, 14 However we cannot 
exclude a significant PTH decrease with a greater patient number, as we observe a 
tendency towards a reduction of plasmatic PTH. 
 
Krause et al. showed that serial whole-body irradiation with an artificial UVB source, in 
contrast to a UVA source, could reduce blood pressure in patients with untreated mild 
hypertension.21 In our study, no change in systolic and diastolic blood pressure could be 
correlated with 25(OH)D levels, but our population was normotensive. The ability to 
synthesize vitamin D decreases with age.22 We were not able to observe any correlation 
between age and vitamin D synthesis, in line with other previous studies.8, 12, 21 We 
observed also no relationship between BMI and vitamin D change, confirming the results 
of previous studies.6, 23 Diagnosis was neither correlated to the extent of serum vitamin D 
change nor to phototherapy modality. It has been shown that the UVBnb course 
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increases 25(OH)D in the healthy subject similarly to the patients with psoriasis and 
atopic dermatitis9, implying that inflamed skin is also able to produce 25(OH)D under the 
influence of UVBnb.   
 
Missing data hampered the analysis of the quality of life index in our study: complete 
information (DLQI before and after therapy) was available for 25 patients only. DLQI 
data was sufficiently complete, however, to document an increase in health related 
quality of life along phototherapy, while the number of completed questionnaires may 
limit the observed lack of correlation to serum vitamin D changes. 
 
The strength of our study is the prospective design with standardized treatments and 
blood analysis. Among the main limitations of the study is the study design: this open 
randomized trial may be biased compared to a randomized controlled trial. Moreover, 
the type of phototherapy was chosen according to the dermatological diagnosis, 
excluding randomization. The different therapy groups are composed of heterogeneous 
diagnoses, and an influence of a precise skin disease cannot be excluded. Bias may 
have arisen from patient preference for treatment at our center, from referral, from 
unrecognized differences in underlying skin disease and other factors. The basal vitamin 
D level was comparable, independent of the diagnosis, but we cannot rule out a possible 
effect of different skin diseases on the individual susceptibility to UVA and/or UVB. 
 
In conclusion, phototherapy has an impact on 25(OH)D levels in the serum. UVBnb is a 
potent inducer of serum 25(OH)D reaching considerable effects already after 2 weeks. 
Notably, UVA1 therapy led to a decrease in serum 25(OH)D levels, suggesting that 
wavelength spectrum of photoexposure is important. While phototherapy induced 
25(OH)D synthesis irrespective of age, gender, BMI, season of the year or underlying 
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skin condition, and increases were biologically relevant under UVBnb as well as under 
UVA/UVBnb, we think that oral supplementation is more appropriate to correct 25(OH)D 
deficiency and to maintain adequate 25(OH)D levels in order to avoid the pro 
carcinogenic effect of UVB.24, 25  Particular wave-lengths such as UVA1 and presumably 
also sunbeds which emit mainly UVA may not be helpful for vitamin D synthesis or even 
be detrimental, thus calling for attention to oral vitamin D supplementation in individuals 
concerned. Our study data calls for closer examination of a potential confounding effect 
of various skin diseases and of the need for oral vitamin D supplementation in UVA1-
treated patients.   
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Table 1: Multivariate analysis for change in vitamin D serum level between 
beginning and end of therapy 
Univariate analysis 
     (adjusted for therapy) 
Change in vit D 
level 
Multiple linear regression 
R2(adj)=0.582 
  beta p 95% CI 
age p = 0.905    
gender p = 0.033 7.2 0.02 1.1; 13.2 
BMI p = 0.85    
blood pressure p = 0.208    
UVA1 therapy p <0.001 -17.457 <0.001 -24.013; 
-10.901 
UVA/UVBnb therapy 11.144  3.789; 
18.498 
UVBnb therapy    
season p = 0.012 12.3 (0,0) 0 
7.5 (0,1) 1 
4.1 (1,0) 2 
baseline (1,1) 3 
0.028 3.945; 
20.579 
0.111; 
14.903 
-3.197; 
11,469 
diagnosis (4=baseline) p = 0.634    
calcium p = 0.098    
phosphate p = 0.124    
log (CRP) p = 0.651    
 19 
PTH/ change in PTH p = 0.596/ p = 
0.433 
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Table 2: Serum concentrations of vitamin D before and after 12-week UV therapy 
 At onset  
mean (median) 
[ng/ml] 
After treatment 
mean (median) 
[ng/ml] 
Change in 
serum [ng/ml] 
p-value 
25(OH)D  
after UVBnb 
22.058 +/- 10.3  
(21.900) 
39.467 +/- 12.2  
(38.300) 
18.6 +/- 4.6 p<0.001  
25(OH)D after 
UVA/UVBnb 
23.917 +/- 20.2  
(20.050) 
50.278 +/- 22.9  
(44.750) 
29.7 +/- 3.7 p=0.003 
25(OH)D after 
UVA1 
21.900  +/-  9.7  
(21.400) 
18.984 +/- 8.3  
(18.600) 
- 1.1 + /- 3.3  p<0.001 
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Table 3: Diagnosis and phototherapy 
Therapy Diagnosis (number of cases*) 
UVA1 Morphoea (13), scleroderma (4), lichen 
sclerosus et atrophicus, atrophoderma 
idiopathica et progressive, cutaneous 
verrucous lupus erythematodes, melanosis 
circumscripta, oid-oid, telangiectasia 
macularis eruptiva perstans, melanosis 
circumscripta 
UVA/UVBnb Atopic dermatitis (16), other eczems (6), 
prurigo simplex subacuta (3), lichen planus 
UVBnb Psoriasis (25), vitiligo (5), mycosis 
fungoides (2), Mallorca acne 
*When number of cases not indicated: unique case.
 22 
Figure legends 
Figure 1 
Patient flow chart 
Figure 2a 
Vitamin D change after 2 weeks phototherapy 
Figure 2b 
Vitamin D change after 12 weeks phototherapy 
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Figure 1: Patient flow chart 
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Figure 2a: Vitamin D change after 2 weeks phototherapy 
 
 25 
Figure 2b: Vitamin D change after 12 weeks phototherapy 
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